Skip to content

EFFECT OF DIET THERAPY AND VYOSHADI SAKTU IN REDUCING OBESITY- A COMPARATIVE STUDY

A COMPARATIVE CLINICAL STUDY TO EVALUATE THE ROLE OF DIET THERAPY AND VYOSHADI SAKTU IN OBESITY

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/11/006333
Enrollment
60
Registered
2015-11-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Obese, Non DM, Non HTN

Interventions

Intervention1: Vyoshdi sakthu: its an Drug Forulation is in the Use in ayurveda for managing Obesity. Control Intervention1: Diet Therapy: Diet of the patient is regulated

Sponsors

Government Ayurveda Medical college Mysore
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Elevated levels of lipid profile • BMI between >30 to 40kg/m2 • Willing to come for regular follow-up visits • Able to give written information consent

Exclusion criteria

Exclusion criteria: • Intake of over the counter weight loss agents, centrally acting appetite suppressants in the previous six months • Pathophysiological/ genetic syndromes associated with obesity (Cushingâ??s syndrome, Turnerâ??s syndrome, Prader willi syndrome) • Patients with evidence of malignancy • Patients with poorly controlled Diabetes Mellitus (HbA1c > 10%) • Patients with poorly controlled Hypertension ( >160/100 mm Hg) • Patients on prolonged ( > 6 weeks) medication with corticosteroids, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study • Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Tuberculosis, Psycho-Neuro-Endocrinal disorders etc.) • Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infraction, Stroke or Severe Arrhythmia in the last 6 months • Symptomatic patient with clinical evidence of Heart failure. • Patients with concurrent serious hepatic disorder (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) > 2.5 times upper normal limit) or Renal Disorders (defined as S.Creatinine > 1.2mg/dL), Severe Pulmonary Dysfunction (uncontrolled Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease (COPD), or any other condition that may jeopardize the study. . • History of HIV and other viral infections • Alcoholics and/or drug abusers • Prior surgical therapy for obesity • History of hypersensitivity to any of the herbal extracts or dietary supplements. • Pregnant/ lactating women. • Patients who have completed participation in any other clinical trial during the past six (03) months. • Any other condition which the principal investigator thinks may jeopardize the study

Design outcomes

Primary

MeasureTime frame
Decrease in body weight and body mass index Decrease in waist circumference and waist hip ratio (anthropometric measurements) Timepoint: 30 days

Secondary

MeasureTime frame
Decrease in cholesterol, Triglycerides, LDL and VLDL values from baseline Increase in HDL values from baseline Increase in the levels of serum calcium and BMD Timepoint: 30 days

Countries

India

Contacts

Public ContactDr Anand Katti

Govt. Ayurveda Medical college,

ayurvedananda@gmail.com9886028646

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026